First Patient Dosed with Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
“We are very pleased to reach this important milestone and with such an encouraging rate of enrollment in our CRB-701 program,” said Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus. “CRB-701 data demonstrates differentiated safety, tolerability and efficacy profiles in HNSCC, cervical and mUC tumors.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.